Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT01986426CT.gov LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Second Affiliated Hospital of Guangzhou Medical University | P2 | B · 57 |
| Nepenthe | Instituto Nacional de Cancer, Brazil | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P3 | BB |
| Lidocaine | Instituto Nacional de Cancer, Brazil | P3 | BB |
| Carboplatin | Rapa Therapeutics LLC | P3 | BB |
| Pembrolizumab | Thomas Jefferson University | P3 | BB |
| Nivestim | University of Colorado, Denver | P2 | BB |
| Epirubicin | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Zelluna Immunotherapy AS | P3 | BB |
+41 more in the Head And Neck Cancer cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Head And Neck Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-head-and-neck-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →